Yuhan Corp. receives IR52 Chang Young Sil award

Published: 2006-07-25 06:57:00

Updated: 2006-07-25 06:57:00

The development of a branded product Voglicose (voglibose) for the treatment of diabetes using a platform technology that shows far more economical and simpler than the existing patented methods has Yuhan Corporation the domestically prestigious IR52 Chang Young Sil Award, the Korea Industrial Te...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK